OliX Pharmaceuticals
OliX Pharmaceuticals is a clinical stage pharmaceutical company developing therapeutics based on proprietary RNAi technology. The company focuses on next-generation RNAi therapeutics, including asiRNA, cp-asiRNA, and GalNAc-asiRNA platforms, targeting various diseases such as dermal, ophthalmic, pulmonary, and liver diseases. With a robust platform technology and strategic collaborations, OliX aims to contribute to global healthcare and become a leading nucleic acid therapeutics company. The company is committed to safety, social responsibility, and ethical practices, as evidenced by its ESG policies, safety management policies, and certifications such as ISO37001 for anti-bribery management.
Industries
Nr. of Employees
medium (51-250)
OliX Pharmaceuticals
Suwon, Ch'ungch'ong-namdo, South Korea, Asia
Products
OLX101A
A treatment designed to inhibit the formation of hypertrophic and keloid scars by targeting the CTGF gene, reducing collagen production.
OLX301A
A treatment for both dry and wet age-related macular degeneration, targeting genes responsible for retinal pigment epithelial cell damage.
OLX301D
Targets CTGF to inhibit choroidal neovascularization and subretinal fibrosis, addressing a high unmet medical need in retinal diseases.
OLX702A
A treatment for metabolic dysfunction-associated steatohepatitis (MASH), targeting genes identified through GWAS to improve liver conditions.
OLX703A
A treatment for Hepatitis B, targeting common sequences in all HBV transcripts to reduce surface antigen levels in the blood.
OLX104C
A hair loss treatment that reduces androgen receptor expression to prevent male pattern baldness, applied locally to the scalp.
OLX101A
A treatment designed to inhibit the formation of hypertrophic and keloid scars by targeting the CTGF gene, reducing collagen production.
OLX301A
A treatment for both dry and wet age-related macular degeneration, targeting genes responsible for retinal pigment epithelial cell damage.
OLX301D
Targets CTGF to inhibit choroidal neovascularization and subretinal fibrosis, addressing a high unmet medical need in retinal diseases.
OLX702A
A treatment for metabolic dysfunction-associated steatohepatitis (MASH), targeting genes identified through GWAS to improve liver conditions.
OLX703A
A treatment for Hepatitis B, targeting common sequences in all HBV transcripts to reduce surface antigen levels in the blood.
OLX104C
A hair loss treatment that reduces androgen receptor expression to prevent male pattern baldness, applied locally to the scalp.
Services
Platform development for RNAi-based therapeutics
Research and development of RNAi-based platform technologies and delivery formats for local and liver-targeted administration.
Lead discovery and candidate optimization for oligonucleotides
Discovery, design and optimization services to produce lead oligonucleotide candidates suitable for preclinical development.
Preclinical pharmacology and efficacy studies
In vivo pharmacology and efficacy testing in disease models, including studies in non-human primates where applicable.
Analytical development for purity and stability
Development and validation of analytical methods to support identity, purity and stability testing for nonclinical and clinical programs.
Bioanalytical PK/TK services
Quantitative bioanalysis of therapeutic candidates in biological matrices to support pharmacokinetic and toxicokinetic studies.
CMC and manufacturing support
Management of manufacturing, process development, analytics and quality control activities for therapeutic candidates.
Platform development for RNAi-based therapeutics
Research and development of RNAi-based platform technologies and delivery formats for local and liver-targeted administration.
Lead discovery and candidate optimization for oligonucleotides
Discovery, design and optimization services to produce lead oligonucleotide candidates suitable for preclinical development.
Preclinical pharmacology and efficacy studies
In vivo pharmacology and efficacy testing in disease models, including studies in non-human primates where applicable.
Analytical development for purity and stability
Development and validation of analytical methods to support identity, purity and stability testing for nonclinical and clinical programs.
Bioanalytical PK/TK services
Quantitative bioanalysis of therapeutic candidates in biological matrices to support pharmacokinetic and toxicokinetic studies.
CMC and manufacturing support
Management of manufacturing, process development, analytics and quality control activities for therapeutic candidates.
Expertise Areas
- RNAi therapeutics development
- Oligonucleotide chemistry and targeted delivery
- Preclinical pharmacology and toxicology
- Analytical and bioanalytical method development
Key Technologies
- RNA interference (siRNA/asiRNA)
- Self-delivering and cell-penetrating oligonucleotides
- Ligand-conjugation for targeted delivery
- Bioanalytical assays for PK/TK quantitation